NO20091999L - MAPK/ERK kinase inhibitorer - Google Patents

MAPK/ERK kinase inhibitorer

Info

Publication number: NO20091999L
Authority: NO; Norway
Prior art keywords: mapk; kinase inhibitors; erk kinase; erk; mek
Prior art date: 2006-10-23

Application number

NO20091999A

Other languages

English (en)

Norwegian (no)

Inventor

Stephen W Kaldor

Qing Dong

Victoria Feher

Naoki Tomita

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-23

Filing date

2009-05-22

Publication date

2009-07-06

2009-05-22 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2009-07-06 Publication of NO20091999L publication Critical patent/NO20091999L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20091999A 2006-10-23 2009-05-22 MAPK/ERK kinase inhibitorer NO20091999L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86256906P	2006-10-23	2006-10-23
PCT/US2007/082138 WO2008140553A2 (en)	2006-10-23	2007-10-22	Mapk/erk kinase inhibitors

Publications (1)

Publication Number	Publication Date
NO20091999L true NO20091999L (no)	2009-07-06

Family

ID=39954277

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20091999A NO20091999L (no)	2006-10-23	2009-05-22	MAPK/ERK kinase inhibitorer

Country Status (25)

Country	Link
US (4)	US7696218B2 (de)
EP (1)	EP2091941B1 (de)
JP (1)	JP5249939B2 (de)
KR (1)	KR20090071666A (de)
CN (1)	CN101563338A (de)
AR (1)	AR063357A1 (de)
AU (1)	AU2007353385A1 (de)
BR (1)	BRPI0717374A2 (de)
CA (1)	CA2667447A1 (de)
CL (1)	CL2007003041A1 (de)
CO (1)	CO6180442A2 (de)
CR (1)	CR10818A (de)
DO (1)	DOP2009000089A (de)
EA (1)	EA200970407A1 (de)
EC (1)	ECSP099354A (de)
IL (1)	IL198254A0 (de)
MA (1)	MA30889B1 (de)
MX (1)	MX2009004269A (de)
NO (1)	NO20091999L (de)
NZ (1)	NZ577047A (de)
PE (1)	PE20081468A1 (de)
TN (1)	TN2009000151A1 (de)
TW (1)	TW200831100A (de)
WO (1)	WO2008140553A2 (de)
ZA (1)	ZA200903274B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007353385A1 (en) *	2006-10-23	2008-11-20	Takeda Pharmaceutical Company Limited	MAPK/ERK kinase inhibitors
JO2985B1 (ar)	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
JP5453290B2 (ja) *	2007-11-12	2014-03-26	武田薬品工業株式会社	Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
ES2616231T3 (es) *	2008-08-21	2017-06-12	Immunogenics Llc	Formulación para administración oral de proteínas
EP2844643B1 (de) *	2012-04-03	2016-11-30	Bristol-Myers Squibb Company	Pyrimidindioncarboxamid inhibitoren der endothelial lipase
CA2900012A1 (en)	2013-02-08	2014-08-14	Celgene Avilomics Research, Inc.	Erk inhibitors and uses thereof
DK3179858T3 (da)	2014-08-13	2019-07-22	Celgene Car Llc	Forme og sammensætninger af en ERK-inhibitor
DE102015117207A1 (de)	2015-10-08	2017-04-13	Silas Mehmet Aslan	Verfahren zur Herstellung von polythiophenhaltigen Fluiden
IL259810A (en)	2018-06-04	2018-07-31	Yeda Res & Dev	Mitogen-activated protein kinase kinase 7 inhibitors
GB202202297D0 (en)	2022-02-21	2022-04-06	Verona Pharma Plc	Formulation production process
TW202506117A (zh)	2023-06-26	2025-02-16	英商維羅納製藥Ｐｌｃ公司	顆粒組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58152890A (ja) *	1982-03-08	1983-09-10	Takeda Chem Ind Ltd	イソキサゾロピリミジン誘導体
US6251943B1 (en)	1997-02-28	2001-06-26	Warner-Lambert Company	Method of treating or preventing septic shock by administering a MEK inhibitor
ATE344791T1 (de)	1997-07-01	2006-11-15	Warner Lambert Co	2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren
KR20010014362A (ko)	1997-07-01	2001-02-26	로즈 암스트롱, 크리스틴 에이. 트러트웨인	4-브로모 또는 4-요오도 페닐아미노 벤즈히드록삼산유도체 및 ｍｅｋ 억제제로서의 그의 용도
CA2349180A1 (en)	1999-01-13	2000-07-20	Stephen Douglas Barrett	Anthranilic acid derivatives
WO2000075118A1 (en)	1999-06-03	2000-12-14	Vertex Pharmaceuticals Incorporated	INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)
CN1219753C (zh)	2000-07-19	2005-09-21	沃尼尔·朗伯公司	4－碘苯氨基苯氧肟酸的氧合酯
WO2005000818A1 (en)	2003-06-27	2005-01-06	Warner-Lambert Company Llc	5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US7538120B2 (en) *	2003-09-03	2009-05-26	Array Biopharma Inc.	Method of treating inflammatory diseases
AU2004293018B2 (en) *	2003-11-19	2010-02-18	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
EP1838675A1 (de)	2004-11-24	2007-10-03	Laboratoires Serono S.A.	Neue 4-arylamino-pyridon-derivate als mek-inhibitoren zur behandlung von hyperproliferativen erkrankungen
US20060223807A1 (en) *	2005-03-29	2006-10-05	University Of Massachusetts Medical School, A Massachusetts Corporation	Therapeutic methods for type I diabetes
ES2378760T3 (es)	2005-05-18	2012-04-17	Array Biopharma, Inc.	Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
AU2007353385A1 (en) *	2006-10-23	2008-11-20	Takeda Pharmaceutical Company Limited	MAPK/ERK kinase inhibitors
JO2985B1 (ar) *	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
JP5453290B2 (ja)	2007-11-12	2014-03-26	武田薬品工業株式会社	Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
WO2009146034A2 (en) *	2008-03-31	2009-12-03	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors and methods of use thereof

2007
- 2007-10-22 AU AU2007353385A patent/AU2007353385A1/en not_active Abandoned
- 2007-10-22 MX MX2009004269A patent/MX2009004269A/es active IP Right Grant
- 2007-10-22 JP JP2009534802A patent/JP5249939B2/ja active Active
- 2007-10-22 NZ NZ577047A patent/NZ577047A/en not_active IP Right Cessation
- 2007-10-22 KR KR1020097010570A patent/KR20090071666A/ko not_active Withdrawn
- 2007-10-22 US US11/876,635 patent/US7696218B2/en active Active
- 2007-10-22 US US12/446,974 patent/US20100204471A1/en not_active Abandoned
- 2007-10-22 EP EP07874225A patent/EP2091941B1/de active Active
- 2007-10-22 CN CNA2007800471578A patent/CN101563338A/zh active Pending
- 2007-10-22 BR BRPI0717374-1A patent/BRPI0717374A2/pt not_active IP Right Cessation
- 2007-10-22 CA CA002667447A patent/CA2667447A1/en not_active Abandoned
- 2007-10-22 EA EA200970407A patent/EA200970407A1/ru unknown
- 2007-10-22 ZA ZA200903274A patent/ZA200903274B/xx unknown
- 2007-10-22 WO PCT/US2007/082138 patent/WO2008140553A2/en not_active Ceased
- 2007-10-23 AR ARP070104689A patent/AR063357A1/es not_active Application Discontinuation
- 2007-10-23 PE PE2007001430A patent/PE20081468A1/es not_active Application Discontinuation
- 2007-10-23 TW TW096139723A patent/TW200831100A/zh unknown
- 2007-10-23 CL CL200703041A patent/CL2007003041A1/es unknown
2009
- 2009-04-21 IL IL198254A patent/IL198254A0/en unknown
- 2009-04-22 TN TNP2009000151A patent/TN2009000151A1/fr unknown
- 2009-04-23 DO DO2009000089A patent/DOP2009000089A/es unknown
- 2009-05-13 MA MA31870A patent/MA30889B1/fr unknown
- 2009-05-21 EC EC2009009354A patent/ECSP099354A/es unknown
- 2009-05-21 CR CR10818A patent/CR10818A/es not_active Application Discontinuation
- 2009-05-22 CO CO09053035A patent/CO6180442A2/es not_active Application Discontinuation
- 2009-05-22 NO NO20091999A patent/NO20091999L/no not_active Application Discontinuation
2010
- 2010-01-05 US US12/652,570 patent/US7943626B2/en active Active
2011
- 2011-04-07 US US13/082,259 patent/US8088783B2/en active Active

Also Published As

Publication number	Publication date
CO6180442A2 (es)	2010-07-19
WO2008140553A4 (en)	2009-04-30
KR20090071666A (ko)	2009-07-01
ZA200903274B (en)	2010-08-25
MA30889B1 (fr)	2009-11-02
BRPI0717374A2 (pt)	2013-10-29
WO2008140553A2 (en)	2008-11-20
TW200831100A (en)	2008-08-01
MX2009004269A (es)	2009-08-12
CL2007003041A1 (es)	2008-03-24
US20100204471A1 (en)	2010-08-12
US20110190261A1 (en)	2011-08-04
IL198254A0 (en)	2009-12-24
EP2091941B1 (de)	2013-01-23
EA200970407A1 (ru)	2009-12-30
US8088783B2 (en)	2012-01-03
AR063357A1 (es)	2009-01-21
DOP2009000089A (es)	2010-03-31
ECSP099354A (es)	2009-06-30
TN2009000151A1 (en)	2010-10-18
CR10818A (es)	2009-07-07
US7943626B2 (en)	2011-05-17
WO2008140553A3 (en)	2009-02-26
NZ577047A (en)	2011-02-25
US7696218B2 (en)	2010-04-13
CA2667447A1 (en)	2008-11-20
EP2091941A2 (de)	2009-08-26
JP2010507683A (ja)	2010-03-11
US20080125437A1 (en)	2008-05-29
CN101563338A (zh)	2009-10-21
JP5249939B2 (ja)	2013-07-31
US20100113413A1 (en)	2010-05-06
AU2007353385A1 (en)	2008-11-20
PE20081468A1 (es)	2008-12-03

Publication	Publication Date	Title
NO20091999L (no)	2009-07-06	MAPK/ERK kinase inhibitorer
NO20080784L (no)	2008-03-31	Histondeacetylaseinhibitorer
WO2008055236A3 (en)	2008-10-09	Mapk/erk kinase inhibitors
ATE479687T1 (de)	2010-09-15	Kinaseinhibitoren
MY146989A (en)	2012-10-15	Kinase inhibitors
TN2009000249A1 (en)	2010-10-18	Mapk/erk kinase inhibitors
WO2006105127A3 (en)	2007-03-22	Hydroxysteroid dehydrogenase inhibitors
WO2008115890A3 (en)	2009-04-30	Mapk/erk kinase inhibitors
WO2007028135A3 (en)	2007-11-01	Imidazopyridine compounds
WO2006066109A3 (en)	2009-04-23	Hydroxysteroid dehydrogenase inhibitors
WO2009146034A3 (en)	2010-07-15	Mapk/erk kinase inhibitors and methods of use thereof
WO2009156462A3 (en)	2010-05-27	Organic compounds
WO2007061923A3 (en)	2007-11-01	Glucokinase activators
WO2007084390A3 (en)	2007-09-20	Histone deacetylase inhibitors
WO2007075847A3 (en)	2007-10-04	Glucokinase activators
NO20091817L (no)	2009-06-26	Kinase inhibitorer
WO2007117995A3 (en)	2008-01-10	Kinase inhibitors
WO2006122319A3 (en)	2007-11-15	Histone deacetylase inhibitors
UA100190C2 (en)	2012-11-26	Akt and p70 s6 kinase inhibitors
NO20084457L (no)	2009-01-07	Tiazolidinderivater som P13 kinaseinhibitorer
WO2007099171A3 (en)	2007-11-15	Bicyclo-pyrazoles active as kinase inhibitors
WO2009129401A8 (en)	2009-12-17	Kinase inhibitors
WO2008045834A3 (en)	2008-07-24	Kinase inhibitors
DK1711177T3 (da)	2008-09-29	1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer
MX2009003793A (es)	2009-12-14	Inhibidores de cinasa.

Legal Events

Date	Code	Title	Description
2013-05-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application